Physicians' Academy for Cardiovascular Education

CVD in women

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Cecilia Linde - ESC 2019, Paris

What is mendelian randomization?

5' education - Oct. 10, 2019 - Paris, France - Prof. Børge Nordestgaard

A life course perspective on benefits of lower cholesterol

3' education - Oct. 9, 2019 - ESC 2019, Paris, France - George Thanassoulis

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

No improved clinical outcomes with remote ischemic conditioning in STEMI patients undergoing PCI

3' education - Oct. 7, 2019 - Prof. Hans Erik Botker - ESC 2019, Paris

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Paris, France - Prof. Christoph Wanner

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Sep. 30, 2019 - Prof. Brian Ference, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Reduced long-term CV death and MI with complete multivessel revascularization in STEMI

3' education - Sep. 25, 2019 - Paris, France - Prof. Shamir Mehta

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Paris, France - Prof. Nikolaus Marx, MD

Substantial reduction in LDL-c with PCSK9i in the very high-risk acute setting of ACS

5' education - Sep. 24, 2019 - Paris, France - Konstantinos C. Koskinas, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

No beneficial effects of oxygen use in subjects with a heart attack

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Ralph Stewart, New Zealand

Decreased CV risk with an intervention targeting identified barriers to care

3' education - Aug. 31, 2019 - ESC 2019, Paris - Prof. J-D Schwalm

Almost significant effects on CV outcomes with ARNI in HFpEF

3' education - Sep. 23, 2019 - Paris, France - Prof. Dirk Jan van Veldhuisen, MD

Reduced NT-proBNP associated with reverse cardiac remodeling after initiation of ARNI in HFrEF

5' education - Sep. 20, 2019 - Paris, France - James Januzzi, MD

Ischemic outcomes with antithrombotic regimes in AF patients with ACS or undergoing PCI

Literature - Oct. 14, 2019 - Potpara TS, et al. - Europace 2019

A meta-analysis of RE-DUAL PCI, PIONEER AF-PCI and AUGUSTUS compared NOAC- and VKA-based regimens and antithrombotic therapies with and without aspirin for ischemic outcomes and CV and total mortality.

Not only weight loss, but also maintaining a lower weight is important for a good CV risk profile

Literature - Oct. 14, 2019 - Berger SE et al., - J Am Heart Assoc. 2019

In data of the Look AHEAD trial, the effects on CV risk factors of maintaining weight loss were compared with those of weight regain, in year 1 to 4 after a 1-year intensive lifestyle intervention.

Parental smoking increases AF risk in offspring

Literature - Oct. 10, 2019 - Groh CA et al., - J Am Coll Cardiol 2019

Data of the Framingham Original and Offspring Cohorts show that parental smoking during childhood is associated with a higher AF risk, partly because offspring show higher propensity of smoking.

CVD in women

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Cecilia Linde - ESC 2019, Paris
Prof. Cecilia Linde emphasizes known aspects of CVD in women, talks about the role of gender of the physician in outcomes of female patients and about the need for research of CVD in women.

ESC 2019 Prof. Cecilia Linde emphasizes known aspects of CVD in women, talks about the role of gender of the physician in outcomes of female patients and about the need for research of CVD in women.

Identification of determinants of iron deficiency in worsening HF

Literature - Oct. 10, 2019 - Van der Wal H et al., - Eur Heart J 2019

Data of the BIOSTAT-CHF cohort suggest that the etiology of ID in worsening HF is multifactorial and may involve a combination of reduced iron uptake, impaired iron storage and iron loss.

Optimism associated with reduced risk of CV events and all-cause mortality

Literature - Oct. 10, 2019 - Rozanski A, et al. - JAMA Network Open

A meta-analysis of 15 studies with more than 220,000 individuals showed that a mindset of optimism was associated with reduced risk of CV events and all-cause mortality.

What is mendelian randomization?

5' education - Oct. 10, 2019 - Paris, France - Prof. Børge Nordestgaard
Britt Heideman asks prof. Nordestgaard to explain the concept of mendelian randomization, what the advantages are, and how it compares to other research methods.

CSI Paris Britt Heideman asks prof. Nordestgaard to explain the concept of mendelian randomization, what the advantages are, and how it compares to other research methods.

Agreement between EBAC and AMA on conversion of CME credit points

News - Oct. 9, 2019

American participants of CME activities can now apply for conversion of European Board for Accreditation in Cardiology (EBAC) CME points to American Medical Association (AMA) credits.

A life course perspective on benefits of lower cholesterol

3' education - Oct. 9, 2019 - ESC 2019, Paris, France - George Thanassoulis
Helena Oestergaard interviews George Thanassoulis on his research on identifying young individuals who would benefit of LCL-c lowering based on their lifetime CV risk.

CSI Paris Helena Oestergaard interviews George Thanassoulis on his research on identifying young individuals who would benefit of LCL-c lowering based on their lifetime CV risk.

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD
Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.

ESC 2019 Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.

No improved clinical outcomes with remote ischemic conditioning in STEMI patients undergoing PCI

3' education - Oct. 7, 2019 - Prof. Hans Erik Botker - ESC 2019, Paris
Prof. Botker gives a brief summary of the CONDI-2/ERIC-PPCI trial, which evaluated whether remote ischemic remodeling results in improved outcomes in STEMI patients undergoing PCI.

ESC 2019 Prof. Botker gives a brief summary of the CONDI-2/ERIC-PPCI trial, which evaluated whether remote ischemic remodeling results in improved outcomes in STEMI patients undergoing PCI.

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD
Prof. Sattar shows that CV risk is heterogenous in patients with diabetes, and explains why new diabetes drugs, such as GLP-1RAs, are recommended for patients with diabetes and CV risk.

Prof. Sattar shows that CV risk is heterogenous in patients with diabetes, and explains why new diabetes drugs, such as GLP-1RAs, are recommended for patients with diabetes and CV risk.

Agenda